FR21C1033I2 - Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale - Google Patents

Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale

Info

Publication number
FR21C1033I2
FR21C1033I2 FR21C1033C FR21C1033C FR21C1033I2 FR 21C1033 I2 FR21C1033 I2 FR 21C1033I2 FR 21C1033 C FR21C1033 C FR 21C1033C FR 21C1033 C FR21C1033 C FR 21C1033C FR 21C1033 I2 FR21C1033 I2 FR 21C1033I2
Authority
FR
France
Prior art keywords
tetrahydroxyl
estrogen
delivery system
drug delivery
hormonal contraception
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1033C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Estetra SRL
Original Assignee
Estetra SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01201945A external-priority patent/EP1293210B1/fr
Application filed by Estetra SRL filed Critical Estetra SRL
Publication of FR21C1033I1 publication Critical patent/FR21C1033I1/fr
Application granted granted Critical
Publication of FR21C1033I2 publication Critical patent/FR21C1033I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
FR21C1033C 2001-05-23 2021-07-27 Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale Active FR21C1033I2 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP01201945A EP1293210B1 (fr) 2001-05-23 2001-05-23 Kit et méthode contraceptive hormonale
EP01201946 2001-05-23
EP01201947 2001-05-23
EP01204377 2001-11-15
EP02075695 2002-02-21
PCT/NL2002/000331 WO2002094279A1 (fr) 2001-05-23 2002-05-23 Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale
EP02738961A EP1390042B1 (fr) 2001-05-23 2002-05-23 Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale

Publications (2)

Publication Number Publication Date
FR21C1033I1 FR21C1033I1 (fr) 2021-10-15
FR21C1033I2 true FR21C1033I2 (fr) 2022-04-22

Family

ID=27513107

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1033C Active FR21C1033I2 (fr) 2001-05-23 2021-07-27 Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale

Country Status (12)

Country Link
US (1) US7732430B2 (fr)
EP (1) EP1390042B1 (fr)
CA (1) CA2448278C (fr)
CY (1) CY1108093T1 (fr)
DE (1) DE60223795T2 (fr)
DK (1) DK1390042T3 (fr)
ES (1) ES2296943T3 (fr)
FR (1) FR21C1033I2 (fr)
LU (1) LUC00213I2 (fr)
NL (1) NL301115I2 (fr)
PT (1) PT1390042E (fr)
WO (1) WO2002094279A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318092T2 (de) 2002-10-23 2008-11-27 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
EP1562976B1 (fr) 2002-11-08 2010-05-26 Pantarhei Bioscience B.V. Synthese d'esterol par l'intermediaire de steroides derives d'estrone
CN107266514A (zh) 2011-06-01 2017-10-20 埃斯特拉私人有限责任公司 用于产生雌四醇中间体的方法
SG195121A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
EP2383279A1 (fr) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
WO2013012326A1 (fr) * 2011-07-19 2013-01-24 Pantarhei Bioscience B.V. Comprimé contenant de la déhydroépiandrostérone (dhea)
LT2741824T (lt) * 2011-08-11 2017-06-26 Estetra S.P.R.L. Estetrolio panaudojimas kaip skubaus kontraceptiko
WO2013034780A2 (fr) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Procédé de préparation de l'estétrol et de composés analogues
JP6254289B2 (ja) 2013-09-18 2017-12-27 クリスタル ファルマ、エセ、ア、ウＣｒｙｓｔａｌ Ｐｈａｒｍａ，Ｓ．Ａ．Ｕ． エステトロールの製造プロセス
DK3079671T3 (en) * 2013-12-12 2017-12-11 Donesta Bioscience B V Orally disintegrating solid dosage unit containing an estetrol component
EP3310333B1 (fr) 2015-06-18 2020-04-29 Estetra SPRL Unité posologique orodispersible contenant un composant d'estétrol
CN107810001A (zh) 2015-06-18 2018-03-16 密特拉制药公司 含雌四醇的口腔分散片剂
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
UA123098C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
CA3178291A1 (fr) 2016-08-05 2018-04-12 Estetra Srl Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
SG11202007163WA (en) * 2018-02-07 2020-08-28 Estetra Sprl Contraceptive composition with reduced cardiovascular effects
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
WO2023152682A1 (fr) 2022-02-10 2023-08-17 Estetra Srl Procédés contraceptifs avec effets de saignements périodiques

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2426779A1 (de) 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336433A1 (de) 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336434A1 (de) 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) * 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
AU2103495A (en) 1994-08-04 1996-03-04 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
EP0994718B1 (fr) 1997-06-20 2005-08-17 Akzo Nobel N.V. Antagoniste de gonadoliberine
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
AU4543200A (en) 1999-04-16 2000-11-02 Dittgen, Michael Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones
WO2000073416A1 (fr) 1999-05-28 2000-12-07 University Of Cincinnati Oligonucleotides antisens regulateurs de la fecondite et du cycle menstruel, et a usage chimiopreventif et chimiocuratif
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
WO2001085154A2 (fr) 2000-05-12 2001-11-15 Oregon Health Sciences University Procede de traitement de pathologies immunitaires grace a de faibles doses d'oestrogene
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1260225A1 (fr) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Compositions pharmaceutiques pour le traitement hormonal substitutif
WO2003041718A1 (fr) * 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Utilisation de composes oestrogenes combines a des composes progestogenes en therapie de substitution hormonale

Also Published As

Publication number Publication date
PT1390042E (pt) 2008-03-10
CA2448278A1 (fr) 2002-11-28
DE60223795T2 (de) 2008-11-27
NL301115I2 (nl) 2021-10-25
WO2002094279A1 (fr) 2002-11-28
US20040198710A1 (en) 2004-10-07
LUC00213I1 (fr) 2021-07-08
EP1390042A1 (fr) 2004-02-25
DE60223795D1 (de) 2008-01-10
NL301115I1 (fr) 2021-07-14
FR21C1033I1 (fr) 2021-10-15
DK1390042T3 (da) 2008-03-31
ES2296943T3 (es) 2008-05-01
CY1108093T1 (el) 2014-02-12
EP1390042B1 (fr) 2007-11-28
CA2448278C (fr) 2010-06-08
LUC00213I2 (fr) 2021-10-29
US7732430B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
FR21C1033I2 (fr) Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale
FR2792842B1 (fr) Systeme de delivrance de bolus de medicament
EP1091732A4 (fr) Systeme d'administration de medicaments effervescents par voie orale
EP1416920A4 (fr) Systeme multiplexe de liberation de medicaments approprie a l'administration par voie orale
HUP0300882A3 (en) New self emulsifying drug delivery system
AU7333601A (en) Drug delivery management system
EP1150629A4 (fr) Unite posologique medicamenteuse pour l'administration par voie buccale d'agents actifs a base de steroides
HUP0401438A3 (en) Drug delivery system
IL157771A0 (en) Intravaginal drug delivery devices for the administration of an antimicrobial agent
EP1239831A4 (fr) Compositions pharmaceutiques ameliorees pour medicaments peu solubles
FR2795967B1 (fr) Systeme de protection d'un dispositif implantable d'administration de medicament vis-a-vis d'un remplissage excessif
HK1034898A1 (en) Topical compositions for nsai drug delivery.
GB0111762D0 (en) Drug delivery mask for animals
HUP0401281A3 (en) Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals
HK1048427A1 (en) Drug delivery device.
BR9609645A (pt) Inalador para a administração de medicamentos a partir de embalagens de ampola
NZ513700A (en) Oral drug delivery system
NO20004196D0 (no) Innretninger for legemiddelavlevering
HK1077523A1 (en) Proliposomal drug delivery system
IL151380A0 (en) New self emulsifying drug delivery system
HRPK20010706B1 (en) Tolperison-containing, pharmaceutical preparation for oral administration
EE05415B1 (et) Ravimi manustamise vahend, eriti androgeenide manustamiseks
FR2796287B1 (fr) Dispositif d'administration de medicament
AU2001258442A1 (en) Drug delivery device, especially for the delivery of levonorgestrel
HK1043944A1 (en) A novel drug delivery system: formulation for fat-soluble drugs.